161 related articles for article (PubMed ID: 34705263)
1. Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.
Denys IB; Gao J; Sutphen JC; Zaveri NT; Kapusta DR
Br J Pharmacol; 2022 Jan; 179(2):287-300. PubMed ID: 34705263
[TBL] [Abstract][Full Text] [Related]
2. Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.
Kapusta DR; Burmeister MA; Calo' G; Guerrini R; Gottlieb HB; Kenigs VA
J Pharmacol Exp Ther; 2005 Aug; 314(2):643-51. PubMed ID: 15855356
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.
Kapusta DR; Thorkildsen C; Kenigs VA; Meier E; Vinge MM; Quist C; Petersen JS
J Pharmacol Exp Ther; 2005 Aug; 314(2):652-60. PubMed ID: 15855355
[TBL] [Abstract][Full Text] [Related]
4. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice.
Burmeister MA; Ansonoff MA; Pintar JE; Kapusta DR
J Pharmacol Exp Ther; 2008 Sep; 326(3):897-904. PubMed ID: 18539652
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
8. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
9. Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system.
Wainford RD; Kapusta DR
Am J Physiol Regul Integr Comp Physiol; 2009 Feb; 296(2):R280-8. PubMed ID: 18987291
[TBL] [Abstract][Full Text] [Related]
10. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
Zaveri NT
J Med Chem; 2016 Aug; 59(15):7011-28. PubMed ID: 26878436
[TBL] [Abstract][Full Text] [Related]
12. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
13. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
Rutten K; Tzschentke TM; Koch T; Schiene K; Christoph T
Eur J Pharmacol; 2014 Oct; 741():264-71. PubMed ID: 25169429
[TBL] [Abstract][Full Text] [Related]
15. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
[TBL] [Abstract][Full Text] [Related]
16. Centrally administered nociceptin/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors.
Burmeister MA; Kapusta DR
J Pharmacol Exp Ther; 2007 Jul; 322(1):324-31. PubMed ID: 17452419
[TBL] [Abstract][Full Text] [Related]
17. Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats.
Kapusta DR; Chang JK; Kenigs VA
J Pharmacol Exp Ther; 1999 Apr; 289(1):173-80. PubMed ID: 10087001
[TBL] [Abstract][Full Text] [Related]
18. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.
Micheli L; Di Cesare Mannelli L; Guerrini R; Trapella C; Zanardelli M; Ciccocioppo R; Rizzi A; Ghelardini C; Calò G
Eur J Pharmacol; 2015 May; 754():73-81. PubMed ID: 25704616
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
Naydenova E; Todorov P; Zamfirova R
Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
[TBL] [Abstract][Full Text] [Related]
20. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
